<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="907">
  <stage>Registered</stage>
  <submitdate>2/10/2005</submitdate>
  <approvaldate>2/10/2005</approvaldate>
  <nctid>NCT00232271</nctid>
  <trial_identification>
    <studytitle>The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.</studytitle>
    <scientifictitle>The Effect of Enoxaparin Sodium (Clexane) on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2004-157</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Deep Vein Thrombosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Clexane

Active Comparator: clexane - patients received clexane

No Intervention: non clexane - no clexane given


Treatment: drugs: Clexane


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of deep vein thrombosis</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients undergoing EPS/RFA for the diagnosis and or treatment of SVT based on patient
             history or ECG evidence.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Patients with a past history of DVT or PE.

          -  Patients with a history of clotting disorders

          -  Patients with active malignancies

          -  Patients requiring full heparinisation during and after the procedure.

          -  Chronic atrial flutter and atrial fibrillation ablation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>35</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Royal Melbourne hospital - Melbourne</hospital>
    <postcode>3050 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Melbourne Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Sanofi</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Heart Foundation, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the effect of the anticoagulant(blood thinner) Clexane
      on the development of leg clots following electrophysiology studies (EPS) and or
      radiofrequency ablation (RFA).

      People who suffer heart palpitations will sometimes need hospital admission to undergo an
      electrophysiology study ( and or a Radiofrequency Ablation)in order to diagnose and or treat
      their condition.

      Radiofrequency ablation is a procedure to stop abnormal heart rhythms. EPS/RFA studies
      require the puncture of the leg veins . Previous experience has shown that following the
      puncture of leg veins there is a small risk of developing a blood clot in the leg.

      It is not known whether giving blood thinners (anticoagulants) after the procedure will
      decrease this risk Enoxaparin Sodium (Clexane) is an anticoagulant used extensively and
      safely following bone (Orthopaedic) surgery to prevent blood clots from developing in the
      legs</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00232271</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paul Sparks, MBBS, PhD. FRACP</name>
      <address>Melbourne Health</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>